View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 18, 2022

Genetic Technologies and Siles Health partner on geneType Multi-Risk Test

The test identifies risks for diseases that include ovarian cancer, type 2 diabetes, prostate cancer, breast cancer and coronary artery disease.

Genetic Technologies (GTG) is collaborating with Obstetrics and Gynaecology practice Siles Health to implement the geneType Multi-Risk Test.

The geneType Multi-Risk Test has been designed to identify an individual’s risk of developing various common serious diseases.

It identifies the sporadic (non-inherited) risk that accounts for up to 85% of diagnosed cases of diseases that include ovarian cancer, type 2 diabetes, prostate cancer, colorectal cancer, breast cancer and coronary artery disease.

Knowing the risk of developing a disease allows the patient and their healthcare provider to put together a personalised preventive health plan.

As part of the collaboration, the geneType Multi-Risk Test will be implemented in nine Obstetrics and Gynaecology clinics belonging to Siles Health, a company that treats more than 15,000 patients each year.

GTG CEO Simon Morriss said: “Adoption of geneType Multi-Risk Test by Siles Health provides GTG with immediate access to an important and expanding group of patients, with the opportunity to make a significant improvement in their health outcomes.

“This partnership also represents another significant milestone along our pathway, the successful commercialisation of geneType Multi-Risk Tests.”

Siles Health will provide a dedicated in-house genetic counselling service to create personalised preventative pathways for patients that are identified as having a high risk of developing a disease.

The company will also refer patients to physicians that can provide dedicated genetic counselling support.

Siles Health founder Charles Siles said: “geneType Multi-Risk Test is a critical risk identification tool to assist our practice to identify potentially high-risk patients and develop truly actionable, personalised, preventative health plans.”

GTG stated that the partnership deal provides a framework for establishing a consistent standard of care for physicians and patients for the test.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network